RSV Drug

View All

beyfortus-for-respiratory-syncytial-virus-treatment
Beyfortus: A New Respiratory Syncytial Virus (RSV) Drug for Toddlers

Sanofi’s immunization strategy is taking shape, owing to an authorization that could drive the company and its partner AstraZeneca to the forefront of the respiratory syncytial virus (RSV) treatment battle. The FDA approved Sanofi and AstraZeneca’s monoclonal antibody Beyfortus, also known as nirsevimab, as a preve...

Find More